Showing results (41-50 of 202) with videos related to
Sort By:
Pageof 21
Current Opinion in Investigational Drugs (London, England : 2000)|June 18, 2003
Exenatide. Amylin/Eli LillyNick GiannoukakisCurrent Opinion in Investigational Drugs (London, England : 2000)|October 2, 2007
BIM-51077, a dipeptidyl peptidase-IV-resistant glucagon-like peptide-1 analogNick GiannoukakisIdrugs : the Investigational Drugs Journal|June 12, 2003
NBI-6024 (Neurocrine Biosciences)Nick GiannoukakisCurrent Opinion in Investigational Drugs (London, England : 2000)|November 8, 2006
Drug evaluation: ranirestat--an aldose reductase inhibitor for the potential treatment of diabetic complicationsNick GiannoukakisCardiovascular Diabetology|July 13, 2022
Improvement in insulin sensitivity and prevention of high fat diet-induced liver pathology using a CXCR2 antagonistBrett E Phillips, Louise Lantier, Carl Engman, et al.Frontiers in Immunology|March 25, 2021
Arrest in the Progression of Type 1 Diabetes at the Mid-Stage of Insulitic Autoimmunity Using an Autoantigen-Decorated All-trans Retinoic Acid and Transforming Growth Factor Beta-1 Single Microparticle FormulationBrett E Phillips, Yesica Garciafigueroa, Carl Engman, et al.The Journal of Biological Chemistry|August 15, 2002
Immunosuppressive effects of glucosamineLinlin Ma, William A Rudert, Jo Harnaha, et al.Expert Opinion on Drug Delivery|October 21, 2010
Drug delivery technologies for autoimmune diseaseBrett E Phillips, Nick GiannoukakisBiodrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy|July 10, 2002
Gene and cell therapies for diabetes mellitus: strategies and clinical potentialNick Giannoukakis, Paul D RobbinsDiabetes|July 29, 2003
Prevention of diabetes in NOD mice by administration of dendritic cells deficient in nuclear transcription factor-kappaB activityLinlin Ma, Shiguang Qian, Xiaoyan Liang, et al.Pageof 21